Exclusive Summary

• - Core patents and data exclusivity have long expired; 0.25 g IR tablets face no meaningful IP barriers in most markets, enabling rapid distribution deals.
• - Key use-cases span H. pylori eradication, CAP combination therapy, and MAC treatment/prophylaxis, creating tens of millions of treatment opportunities annually.
• - Listed on the WHO Essential Medicines List (for H. pylori eradication) and endorsed by major guidelines under defined conditions, ensuring strong clinical acceptance.
• - Although highly genericized, differentiation is achievable via Zone IVb stability, dissolution equivalence, therapy-ready packs (e.g., 28/56 tablets), and reliable supply.
• - Typically 80–95% cheaper than originator brands, supporting volume growth across tenders and retail with attractive distributor margins.